News

Novo Nordisk: Watching Value Investors Buy The Dip Hurts My Eyes
Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...
Novo Nordisk: Enough Is Enough
Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...
TMCnet1h
Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
On this news, Novo Nordisk's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 2, 2025, thereby injuring investors. What Is The Lawsuit About?
Earnings live: Monday.com stock tanks, AMC set to report as Q2 earnings season starts winding down
The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...
A $236bn growth opportunity!? Is this FTSE 100 stock about to skyrocket?
This FTSE 100 stock could be on the verge of stealing enormous chunks of market share from some of the largest pharmaceutical ...
Earnings live: Micron raises forecast, AMC stock pops, Monday.com stock tanks
The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive.